Related Experiment Video
Updated: Apr 28, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Updated roles of adrenergic receptors in prostate cancer]
Abstract:
Adrenergic receptors are members of the G-protein coupled receptor superfamily. Recent studies revealed that these adrenergic receptors are playing an important role in the growth and metastasis of prostate cancer cells. The expression of adrenergic receptors rises significantly in prostate cancer cells and tissues. Agonists of these receptors promote the growth and mobility of prostate cancer cells, while antagonists may suppress their proliferation, trigger their apoptosis, and inhibit their metastasis. Clinically, receptor antagonists can significantly reduce the risk of prostate cancer and improve its prognosis after androgen depravation therapy. This article presents an overview on the roles of adrenergic receptors in prostate cancer.
Insights
Adrenergic receptors significantly impact prostate cancer growth and spread. Blocking these receptors may inhibit cancer progression and improve patient outcomes.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Context:
- Adrenergic receptors (ARs), a G-protein coupled receptor superfamily, are increasingly implicated in cancer.
- Prostate cancer exhibits significantly elevated AR expression in cells and tissues.
Purpose:
- To provide an overview of the critical roles adrenergic receptors play in prostate cancer.
- To explore the therapeutic potential of targeting ARs in prostate cancer treatment.
Summary:
- ARs influence prostate cancer cell proliferation, migration, and metastasis.
- Agonists of ARs stimulate cancer cell growth and mobility.
- Antagonists of ARs can suppress proliferation, induce apoptosis, and inhibit metastasis.
Impact:
- Targeting ARs with antagonists shows promise for reducing prostate cancer risk.
- AR antagonists may improve patient prognosis, particularly following androgen deprivation therapy.
More Related Videos
Related Concept Videos
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenergic Receptors (Adrenoceptors): Classification
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Sympathetic Signaling
Sympathetic preganglionic fibers release the neurotransmitter acetylcholine (ACh) onto the ganglionic neurons in the...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...

